Soligenix, Inc.
SNGX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000812796
No open-market purchases or sales by Soligenix, Inc. insiders were filed in the last 90 days; 17 institutions reported holding it in 13F filings for Q2 2026, worth $369.6K in total; no superinvestor holds it.
13F holders, Q2 2024
Institutional positions in Soligenix, Inc. as of Jun 30, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 11
- −7 vs. Q1 2024
- Shares held
- 100.4K
- −138.7K (−58.0%) vs. Q1 2024
- Total value
- $259.1K
- +$116.2K (+81.2%) vs. Q1 2024
- New holders
- 4
- 1 more added
- Sold out
- 11
- 6 more reduced
Compare with Q1 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting SNGX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 17 | $369.6K |
| Q1 2026 | 15 | $307.4K |
| Q4 2025 | 19 | $600.0K |
| Q3 2025 | 23 | $1.61M |
| Q2 2025 | 15 | $248.2K |
| Q1 2025 | 11 | $313.1K |
| Q4 2024 | 10 | $82.8K |
| Q3 2024 | 7 | $262.4K |
| Q2 2024 | 11 | $259.1K |
| Q1 2024 | 18 | $143.0K |
| Q4 2023 | 20 | $286.5K |
| Q3 2023 | 19 | $500.2K |
| Q2 2023 | 20 | $1.02M |
| Q1 2023 | 16 | $195.2K |
| Q4 2022 | 36 | $1.37M |
| Q3 2022 | 30 | $1.35M |
| Q2 2022 | 28 | $1.91M |
| Q1 2022 | 33 | $2.38M |
| Q4 2021 | 28 | $2.24M |
| Q3 2021 | 34 | $4.35M |
| Q2 2021 | 34 | $4.59M |
| Q1 2021 | 35 | $5.22M |
Institutions, Q2 2024
Shares, value and share of portfolio for each institution holding Soligenix, Inc.; share changes are against Q1 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Armistice Capital, LLC | 80,000 | $206.4K | 0.01% | +80,000 | New |
| Old National Bancorp | 10,000 | $25.8K | 0.00% | +10,000 | New |
| UBS Group AG | 6,231 | $16.1K | 0.00% | +4,802+336.0% | Added |
| Tower Research Capital LLC (TRC) | 3,672 | $9.47K | 0.00% | −3,295−47.3% | Reduced |
| Plante Moran Financial Advisors, LLC | 300 | $774 | 0.00% | −4,478−93.7% | Reduced |
| Morgan Stanley | 225 | $580 | 0.00% | −3,369−93.7% | Reduced |
| Bank of America Corp | 11 | $29 | 0.00% | −8−42.1% | Reduced |
| Wells Fargo & Company | 1 | $3 | 0.00% | −80−98.8% | Reduced |
| Albion Financial Group | 1 | $3 | 0.00% | −4−80.0% | Reduced |
| FMR LLC | 1 | $3 | 0.00% | +1 | New |
| Trust Co of Vermont | 1 | $3 | 0.00% | +1 | New |
| Geode Capital Management, LLC | 0 | $0 | 0.00% | −56,799−100.0% | Sold out |
| Vanguard Group Inc | 0 | $0 | 0.00% | −50,865−100.0% | Sold out |
| Nomura Holdings Inc | 0 | $0 | 0.00% | −30,000−100.0% | Sold out |
| Warberg Asset Management LLC | 0 | $0 | 0.00% | −24,500−100.0% | Sold out |
| First Wilshire Securities Management Inc | 0 | $0 | 0.00% | −23,334−100.0% | Sold out |
| Two Sigma Investments, LP | 0 | $0 | 0.00% | −12,731−100.0% | Sold out |
| HRT Financial LP | 0 | $0 | 0.00% | −12,518−100.0% | Sold out |
| Two Sigma Securities, LLC | 0 | $0 | 0.00% | −11,435−100.0% | Sold out |
| Advisor Group Holdings, Inc. | 0 | $0 | 0.00% | −53−100.0% | Sold out |
| Brown Brothers Harriman & Co | 0 | $0 | 0.00% | −34−100.0% | Sold out |
| GWM Advisors LLC | 0 | $0 | 0.00% | −3−100.0% | Sold out |